Sylvain Foucart's research while affiliated with University of British Columbia - Vancouver and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (5)
To assess the effect of preservative-free dorzolamide-timolol on nonvisual symptoms and intraocular pressure (IOP) in newly diagnosed and untreated patients with open-angle glaucoma or ocular hypertension.
This was a prospective, 8-week, open-label, Canadian multicenter study. All patients were treated with preservative-free dorzolamide-timolol for...
To evaluate the effectiveness of montelukast as add-on therapy for asthmatic patients who remain uncontrolled with low, moderate or high doses of inhaled corticosteroid monotherapy.
An eight-week, multicentre, open-label, observational study.
Of 320 patients enrolled, 288 (90.0%) completed the study. Of patients who had uncontrolled asthma symptoms...
AIM: To evaluate the effectiveness of montelukast as add-on therapy for asthmatic patients who remain uncontrolled with low, moderate or high doses of inhaled corticosteroid monotherapy.
DESIGN: An eight-week, multicentre, open-label, observational study.
RESULTS: Of 320 patients enrolled, 288 (90.0%) completed the study. Of patients who had uncont...
Citations
... No significant differences were observed for all the variables, including asthma symptoms and lung function (FEV 1 ), between the treated and the placebo group [106,107]. In an 8-week single cohort study (n = 320), montelukast was well tolerated and effective in achieving asthma control and reduction of symptoms [108]. In a 24week double-blind study (n = 191), montelukast reduced the need for high doses of ICS while maintaining the clinical stability of patients [109]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/276892369342469-1443027693203_Q64/J-Mark-Fitzgerald.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272471127490570-1441973587471_Q64/John-Sampalis.jpg)
... Often, patients with glaucoma require lifetime topical therapy and OSD has been reported in up to 59% of patients [4,5]. Preservatives in topical antiglaucoma drops disrupt the ocular surface by a variety of mechanisms resulting in decreased tear film stability and increased evaporation [6,7]. The side effects of preserved eye drop administration include ocular hyperemia, burning, stinging, and itching that are exacerbated by an unstable tear film [7]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272540123791380-1441990037363_Q64/Cindy-Hutnik.jpg)
... The score of patients in the treatment group is significantly higher than that of patients in the control group after treatment for 1 week; * P<0.05. and important mediators of asthma (13). Montelukast is a non-steroidal anti-inflammatory drug, which, as a selective inhibitor of Cys-LT, can relieve the airway spasm by reducing the Cys-LT concentration in patients, thus playing a role in the treatment of acute bronchial asthma (14). ...
